Amarin (FRA:EH3) Stock Based Compensation: €6.9 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:EH3 Amarin Corp PLC FRA:EH3
58 GF Score
Price €12.30
GF Value €9.97
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Amarin Stock Based Compensation?

Amarin FRA:EH3 +1.65% 58 Stock Based Compensation is €6.9 Mil as of Jun. 2026. GuruFocus rates FRA:EH3 with a GF Score™ of 58/100 and a GF Value™ of €9.97 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Amarin's Stock Based Compensation for the three months ended in Jun. 2026 was €1.8 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 was €6.9 Mil.

Amarin Stock Based Compensation Related Terms

Amarin Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Amarin's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amarin Stock Based Compensation Chart

Amarin Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.69 24.75 14.35 16.91 11.90

Amarin Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.24 1.67 1.38 2.02 1.82
FRA:EH3
58GF Score
Amarin Corp PLC FRA:EH3
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amarin Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €6.9 Mil.

What does a Stock Based Compensation of €6.9 Mil mean?
Amarin (FRA:EH3) has a Stock Based Compensation of €6.9 Mil as of Jun. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Amarin and its competitors.
Is Amarin's Stock Based Compensation too high?
Amarin's current Stock Based Compensation is €6.9 Mil. Overall, Amarin has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amarin's Stock Based Compensation compare to SCLX and MIRA?
Amarin's Stock Based Compensation of €6.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Amarin and its competitors. Amarin's current Stock Based Compensation is €6.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amarin stock overvalued right now?
Based on GuruFocus' analysis, Amarin (FRA:EH3) is currently considered Modestly Overvalued. The stock's GF Value™ is €9.97, compared to a current price of €12.30 — trading 23.4% above its estimated fair value. The current Stock Based Compensation is €6.9 Mil. Amarin's overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Amarin (FRA:EH3), the current Stock Based Compensation is €6.9 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amarin (FRA:EH3) Overvalued in 2026?

Based on GuruFocus' analysis, Amarin stock appears to be overvalued. The current stock price of €12.30 is trading 23.4% above its estimated GF Value™ of €9.97. GuruFocus considers Amarin to be Modestly Overvalued.

Key valuation signals for FRA:EH3:

  • Stock Based Compensation: €6.9 Mil
  • GF Value™: €9.97 vs. price of €12.30 (23.4% above fair value)
  • GF Score™: 58/100 with 3 warning signs

No single metric tells the full story. See the FRA:EH3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amarin Business Description

Other Exchanges AMRN:USA
Address 36 Dame Street, 8th Floor, One Central Plaza, Dublin, IRL, D02 K7K5
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.
58GF Score

Get the complete analysis for FRA:EH3

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.30
Price
€9.97
GF Value